Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Stealth BioTherapeutics’ lead drug has failed a Phase II study in an eye disease, dealing another blow to the biotech’s elamipretide as the treatment had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Stealth's lead drug flunks again, this time in an eye dis­ease, but biotech will at­tempt to push for­ward

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward